FDA halts trials of Amgen drug in children, cites death

Your Health Matters

The headquarters of the U.S. Food and Drug Administration is shown in Silver Spring near Washington(Reuters) – The Food and Drug Administration said on Tuesday it has stopped all pediatric clinical trials of Amgen Inc's Sensipar after the death of a 14-year-old patient taking part in a study of the drug. Sensipar, which is approved for adults, is used to lower dangerously high calcium levels in the blood. The agency said it was collecting information on the circumstances of the teenager's death. It said it does not know if the Amgen drug had any role in the death. …

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave